About Us

CEO Message

A Message from Our CEO

"For a healthier future for all,
MediCure takes one more step forward every day."

Dear valued stakeholders,

I am Jung-Hyun Kim, CEO of MediCure Pharmaceuticals. Since our founding in 1987, we have contributed to public health under our core value of "Respect for Life." Over more than 37 years, we have grown into a globally recognized comprehensive pharmaceutical company through relentless R&D and quality innovation.

Amid the rapid advances in biopharmaceuticals, cell and gene therapies, MediCure is building the infrastructure to lead the future of medicine, including our AI-powered drug discovery platform and state-of-the-art biomanufacturing facilities.

Furthermore, we are committed to ESG management, protecting the environment, growing alongside local communities, and operating transparently to earn the trust of all our stakeholders.

Our challenge to improve patients' quality of life and build a healthier future for humanity will continue. We sincerely appreciate your continued interest and support.

Thank you.

CEO, MediCure Pharmaceuticals Jung-Hyun Kim

Vision & Values

Vision & Core Values

MediCure's vision and core values for a better tomorrow

Respect for Life

We place patients at the center of every decision, providing safe and effective medicines to protect human life and health.

Pursuit of Innovation

Through continuous R&D and technological innovation, we develop next-generation therapeutics and lead new paradigms in the pharmaceutical industry.

Building Trust

Based on transparent management and an ethical corporate culture, we strive to be a trusted company by patients, healthcare professionals, shareholders, and communities.

Our Mission

A Global Healthcare Leader
Pioneering a Healthier Future Through Innovative Medicine

History

Our History

37 years of growth and relentless challenge

2025

Global Expansion

Annual revenue of KRW 1.235 trillion
MC-310 Alzheimer's drug enters Phase III
MOU with Daiichi Sankyo for biosimilars

2022

Bio Manufacturing Expansion

Osong BioPlant Factory 2 completed
FDA cGMP certification obtained
CMO business officially launched

2018

R&D Innovation

Pangyo R&D Center established
AI drug discovery platform launched
MC-101 oncology biosimilar enters clinical trials

2012

Global Market Entry

US subsidiary established in New Jersey
Exports to 10 Southeast Asian countries
EU EMA GMP certification

2005

Comprehensive Pharma Company

Listed on KOSDAQ
Product portfolio exceeds 100 items
Osong GMP Factory 1 completed

1995

Strengthening R&D

Central Research Institute established
First in-house developed drug approved
'CurePlus' OTC brand launched

1987

Foundation

MediCure Pharmaceuticals founded
Seoul Gangnam HQ established
"Respect for Life" management philosophy

Global Network

Exporting to over 30 countries worldwide

HQ (Seoul)

521, Teheran-ro
Gangnam-gu, Seoul

R&D Center (Pangyo)

289, Pangyo-ro
Bundang-gu, Seongnam

Plant (Osong)

123, Osong Saengmyeong-ro
Cheongju, Chungbuk

US Office (NJ)

300 Frank W. Burr Blvd.
Teaneck, NJ 07666

Key Certifications

KGMP

Korea MFDS

FDA cGMP

US FDA

EU GMP

European EMA

ISO 14001

Environmental

ISO 45001

Health & Safety